Pulmonary Hypertension in Sarcoidosis
| Autor: | Robert P. Baughman, Peter J. Engel, Steven D. Nathan |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Lung Sarcoidosis business.industry Hypertension Pulmonary medicine.medical_treatment Retrospective cohort study medicine.disease Pulmonary hypertension Bosentan medicine.anatomical_structure medicine.artery Internal medicine Pulmonary artery Cardiology Humans Medicine business Complication medicine.drug Cardiac catheterization |
| Zdroj: | Clinics in Chest Medicine. 36:703-714 |
| ISSN: | 0272-5231 |
| DOI: | 10.1016/j.ccm.2015.08.011 |
| Popis: | Pulmonary hypertension is a complication of sarcoidosis leading to dyspnea and associated with increased morbidity and mortality. Sarcoidosis-associated pulmonary hypertension (SAPH) can be due to several factors, including vascular involvement by the granulomatous inflammation, compression of the pulmonary arteries by adenopathy, fibrotic changes within the lung, and left ventricular diastolic dysfunction. Several case series have suggested that some patients with SAPH benefit from specific therapy for pulmonary hypertension. A randomized, placebo-controlled trial found 16 weeks' bosentan therapy to be associated with significant improvement in pulmonary artery pressure. Future studies may better define who would respond to treatment of pulmonary hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|